NOBIVAC EDGE® DAPPv

NOBIVAC EDGE^® DAPPv is a 0.5mL, combined vaccination approved for protection against canine distemper virus, adenovirus type 1 (hepatitis), canine parainfluenza virus, and canine parvovirus.

Product Description

NOBIVAC EDGE^® DAPPv provides protection against four known viruses in a 0.5ML vaccine

Canine Distemper Virus, Canine Adenovirus 1 (hepatitis), Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses).

Protects against all known strains of CPV, including CPV-2c^2,3
High antigenic mass (titer), low passage parvovirus vaccine
Canine vaccine containing CPV-2b, one of the most prevalent field strains of parvovirus
Protects against adenovirus type 1 that causes hepatitis in dogs
Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1, parainfluenza and parvovirus in 1 formula

Product Label

Overview

Efficacy

Safety

Administration

Alternate

Disease Information

Resources

Indications:

Shown to be effective for the vaccination against distemper, adenovirus type 1 (hepatitis), parainfluenza, and parvovirus in one formula. Recommended for use in healthy dogs 6 weeks of age or older.

Efficacy & Comparisons

NOBIVAC EDGE^®DAPPv IS A SAFE CHOICE

Safety confirmed in 346-dog field study¹
Proven safe across a variety of dog breeds and ages

ADMINISTRATION AND DOSAGE

Subcutaneous injection
Primary vaccination may begin as early as 6 weeks
Repeat dose 2 to 4 weeks later. Two doses are required for primary immunization.
Historically, annual revaccination has been recommended for this product. The need for this booster has not been established.
Available in a 25 x 0.5 mL dose presentation

ALSO AVAILABLE IN OTHER FORMULATIONS

NOBIVAC EDGE^® DAPPv+L₄VACCINES

DISEASE INFORMATION

MORBIDITY THREATS

Signs vary from a slight fever to death.
The mortality rate ranges from 10%–30%.
Severely infected dogs may develop convulsions from forebrain damage.
Paresis, ataxia and central blindness have also been described.
In ~25% of recovered dogs, bilateral corneal opacity develops.

SPREADING DISEASE

The virus is spread in the feces, urine, blood, saliva, and nasal discharge of infected dogs.
Contracted through the mouth or nose, where it replicates in the tonsils.
The incubation period is 4 to 7 days.

DIAGNOSIS

Abrupt onset of illness and bleeding suggest ICH, although clinical evidence is not always sufficient to differentiate ICH from distemper (see Canine Distemper).

PROTECT AGAINST ALL KNOWN STRAINS OF CANINE PARVOVIRUS (CPV), INCLUDING CPV-2C²

PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ²

No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains²
First published data showing protection against CPV-2c challenge²
All vaccinated puppies were protected from disease
All control puppies developed disease and 50% died or were euthanized